Here’s ChemT Biotechnology! They’re a US- and Singapore-based startup building the AI layer for chemistry, manufacturing, and controls in the pharmaceutical industry. 

• They recently raised $4M in seed funding.
• This comes shortly after a previous $1M angel investment.

‍

Investor check. Wavemaker Ventures led the round, while SEEDS joined as a co-investment partner. 

• Wavemaker 360 Health, Draper University Ventures, and participants from the Temasek Life Sciences Accelerator also joined as investors. 

‍

🦠 The ABCs of ChemT

ChemT’s proprietary virtual cell platform CelMo, simulates how cells respond to manufacturing conditions, genetic changes, and other environmental factors. 

• This helps track which biological pathways are activated, suppressed, or rewired. 

‍

🔍 Some of their wins

• 50% increase in antibody output and 40% reduction in production timelines in Chinese hamster ovary cells
• 50% faster development, 3x scalability, 60% lower costs, and 10% higher expansion yield in T-cell manufacturing through their small-molecule product, Chemplify

‍

In the real world. They’ve already signed commercial partnerships with over 40 pharmaceutical, biotech, and contract development and manufacturing organizations.

‍

💸 What’s with the $$$? 

They’ll use the new capital to develop their AI and experimental infrastructure. 

• They’ll also expand Celmo applications to include stem cells, natural killer cells, HEK cells.